Status: Recruiting
Zanidatamab in Combination With Pembrolizumab and Chemotherapy in HER2 and PD-L1 Positive Metastatic Gastroesophageal Adenocarcinoma (GEA) Patients
The ZANGEA trial is a open-label, single arm, multicenter phase II trial assessing the efficacy of zanidatamab in combination with pembrolizumab and chemotherapy in patients with metastatic gastroesophageal adenocarcinoma (GEA). The patients need to be previously untreated in the palliative setting and tested positive for HER2 and PD-L1.
Participants needed: 80
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestUpdated: Jun 30, 2026Locations: 20
Eligibility criteria
Patient* has signed and dated a written informed consent form in accordance with... [+14]
Patient has any known contraindication including allergy or hypersensitivity to... [+17]